Welcome Letter from the Presidents

Dear colleagues and friends,

It is my privilege and honor to welcome you to attend the 24th World Congress of Asthma – WCA-2018 in Tokyo, Japan, organized by the Asthma Global Association-INTERASMA, from October 3 through October 6, 2018.

WCA brings together specialists, physicians and healthcare professionals from all over the world to share valuable scientific knowledge on asthma, ranging from diagnostic and therapeutic tools and techniques to leading-edge research. WCA has been very popular, resulting in highly successful and well-attended congresses with outstanding scientific programs. The 24th World Congress of Asthma – WCA-2018 will not be an exception.

INTERASMA is celebrating its 62nd anniversary of uninterrupted education in the field of asthma, making it the most important international asthma and related diseases organization in the world, as well as a reference organization for primary care physicians, healthcare providers and medical students.

Tokyo, officially Tokyo Metropolis, is the capital city of Japan and one of its 47 prefectures. The Greater Tokyo Area is the most populous metropolitan area in the world. It is the seat of the Emperor of Japan and the Japanese government. Tokyo is in the Kantō region on the southeastern side of the main island Honshu and includes Ogasawara Islands. Tokyo is often referred to as a city, but is officially known and governed as a “metropolitan prefecture”, which differs from and combines elements of a city and a prefecture, a characteristic unique to Tokyo.

Tokyo has many museums. In Ueno Park, there is the Tokyo National Museum, the country’s largest museum specializing in traditional Japanese art; the National Museum of Western Art and Ueno Zoo. Other museums include the National Museum of Emerging Science and Innovation in Odaiba; the Edo-Tokyo Museum in Sumida, across the Sumida River from the center of Tokyo; the Nezu Museum in Aoyama; and the National Diet Library, National Archives, and the National Museum of Modern Art, which are near the Imperial Palace.

Tokyo has many theatres for performing arts. These include national and private theatres for traditional forms of Japanese drama. Noteworthy are the National Noh Theatre and the Kabuki-za for kabuki. Symphony orchestras and other musical organizations perform modern and traditional music. Tokyo also hosts modern Japanese and international pop and rock music at venues ranging in size from intimate clubs to internationally known arenas such as the Nippon Budokan.

It will be our pleasure to welcome you to Tokyo, Japan, on October 2018.

Sincerely,

Professor Lawrence DuBuske
President of GAA Interasma

Professor Ken Ohta
President of the Local Organizing Committee
**XXIV World Congress of Asthma**

**OCTOBER 3-6, 2018, Keio Plaza Hotel**

**Tokyo, Japan**

---

### GAA Interasma Board of Directors

**Executive Committee**

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Lawrence DuBuske, USA</td>
</tr>
<tr>
<td>President Elect</td>
<td>Louis Philippe Boulet, Canada</td>
</tr>
<tr>
<td>First Vice President</td>
<td>Jonathan Bernstein, USA</td>
</tr>
<tr>
<td>Second Vice President</td>
<td>Nelson Rosario, Brasil</td>
</tr>
<tr>
<td>Chief Executive Director &amp; Immediate Past President</td>
<td>Giorgio Walter Canonica, Italy</td>
</tr>
<tr>
<td>Past Past President</td>
<td>Carlos Baena-Cagnani, Argentina</td>
</tr>
<tr>
<td>Secretary General</td>
<td>Fulvio Braido, Italy</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Ignacio Ansotegui, Spain</td>
</tr>
<tr>
<td>Historian</td>
<td>Carlos Nunes, Portugal</td>
</tr>
<tr>
<td>A.M.C.</td>
<td>Niki Gargassoula, Greece</td>
</tr>
</tbody>
</table>

### Members At Large

- Alvaro Cruz, Brasil
- Sandra Gonzalez-Diaz, Mexico
- Georgii Gudima, Russia
- Juan Carlos Ivancevich, Argentina
- Piotr Kuna, Poland
- Catherine Lemiere, Canada
- Shigenori Nakajima, Japan
- Ken Ohta, Japan
- Helen Reddel, Australia
- Gustavo Rodrigo, Uruguay
- Michael Wechsler, USA
- Arzu Yorgancioglu, Turkey

### Adjunct Members

- Juan Celedon, USA
- Kunio Dobashi, Japan
- Fernando Holguin, USA
- Giovanni Passalacqua, Italy
- Ruby Pawankar, Japan
- Franscesca Puggioni, Italy
- Osman Yusuf, UK
- Mario Zernotti, Argentina
Scientific Programme Committee

<table>
<thead>
<tr>
<th>Lawrence DuBuske, USA</th>
<th>Louis Philippe Boulet, Canada</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giorgio Walter Canonica, Italy</td>
<td>Fulvio Braido, Italy</td>
</tr>
</tbody>
</table>

Scientific Advisory Board

<table>
<thead>
<tr>
<th>Eugenio Baraldi, Italy</th>
<th>Giovanni Passalacqua, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francesco Blasi, Italy</td>
<td>Ian Pavord, UK</td>
</tr>
<tr>
<td>Jean Bousquet, France</td>
<td>Ruby Pawankar, Japan</td>
</tr>
<tr>
<td>Andy Bush, UK</td>
<td>Gustavo Rodrigo, Uruguay</td>
</tr>
<tr>
<td>Juan Celedon, USA</td>
<td>Lanny Rosenwasser, USA</td>
</tr>
<tr>
<td>Adnan Custovic, UK</td>
<td>Dirceu Sole, Brazil</td>
</tr>
<tr>
<td>Gennaro D' Amato, Italy</td>
<td>James Sublett, USA</td>
</tr>
<tr>
<td>Ronald Dahl, Denmark</td>
<td>Mario Sanchez-Borges, Venezuela</td>
</tr>
<tr>
<td>Stephen T. Holgate, UK</td>
<td>Johann Christian Virchow, Germany</td>
</tr>
<tr>
<td>Peter Le Souef, Australia</td>
<td></td>
</tr>
</tbody>
</table>
# INTERASMA JAPAN

## Board of Directors Interasma/Japan

<table>
<thead>
<tr>
<th><strong>Honorary President</strong></th>
<th>Shigenori Nakajima</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Honorary Advisors</strong></td>
<td>Terumasa Miyamoto, Sankei Nishima</td>
</tr>
<tr>
<td><strong>President</strong></td>
<td>Ken Ohta</td>
</tr>
<tr>
<td><strong>Vice-Presidents</strong></td>
<td>Yuji Tohda, Kunio Dobashi</td>
</tr>
<tr>
<td><strong>Secretary General</strong></td>
<td>Masami Taniguchi</td>
</tr>
</tbody>
</table>

## Local Organizing Committee/Japan

<table>
<thead>
<tr>
<th><strong>Chair of Organizing Committee</strong></th>
<th>Mitsuru Adachi</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Co-chairs of Organizing Committee</strong></td>
<td>Yuji Tohda, Shu Hashimoto</td>
</tr>
<tr>
<td><strong>Chairs of Program Committee</strong></td>
<td>Hironori Sagara, Masao Yamaguchi</td>
</tr>
<tr>
<td><strong>Co-chairs of the Program Committee</strong></td>
<td>Hironori Sagara, Masami Taniguchi</td>
</tr>
</tbody>
</table>

## Steering Committee/Japan

<table>
<thead>
<tr>
<th>Akio Niimi</th>
<th>Shigemi Yoshihara</th>
</tr>
</thead>
<tbody>
<tr>
<td>Masakazu Ichinose</td>
<td>Takeshi Hisada</td>
</tr>
<tr>
<td>Hiromasa Inoue</td>
<td>Yasuyuki Sano</td>
</tr>
<tr>
<td>Hiroyuki Nagase</td>
<td>Shigemi Yoshihara</td>
</tr>
<tr>
<td>Koichiro Asano</td>
<td>Yuichi Adachi</td>
</tr>
<tr>
<td>Hirokazu Arakawa</td>
<td>Naoki Shimojo</td>
</tr>
</tbody>
</table>

## Financial Committee/Japan

<table>
<thead>
<tr>
<th>Shu Hashimoto</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jun Tamaoki</td>
</tr>
<tr>
<td>Takahiko Horiguchi</td>
</tr>
</tbody>
</table>
## CONGRESS TOPICS

### ACUTE ASThma
- Causes and risk factors
- Management and prevention
- Lessons from emergency room management of asthma

### ALLERGEN IMMUNOTHERAPY
- Current standards
- Oral immunotherapy update
- Role of SLIT in asthma

### ALLERGIC RHINITIS IMPACT ON ASThma
- Shared pathophysiology of allergic rhinitis and asthma
- Impact of allergic rhinitis therapies in asthma
- Allergen immunotherapy in asthma
- Sub lingual allergen immunotherapy for dust mite in asthma and allergic rhinitis
- Safety of subcutaneous versus sublingual immunotherapy in asthma

### ALLERGY
- Allergy testing
- Aero-allergens and airways
- The ARIA initiative

### ANAPHYLAXIS
- Pathophysiology
- Food allergy
- Venom allergy
- Drug allergy
- Treatment paradigms for anaphylaxis
<table>
<thead>
<tr>
<th>Category</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASTHMA AND COPD</strong></td>
<td>Role of eosinophils in ACOS</td>
</tr>
<tr>
<td></td>
<td>Role of Th2 inflammation in ACOS</td>
</tr>
<tr>
<td></td>
<td>Heterogeneity of immune pathogenesis of asthma and COPD</td>
</tr>
<tr>
<td></td>
<td>Assessment of benefits of new LAMAs in asthma and COPD</td>
</tr>
<tr>
<td></td>
<td>ICS plus LABA plus LAMA in asthma and COPD</td>
</tr>
<tr>
<td></td>
<td>Role of new biologicals in COPD</td>
</tr>
<tr>
<td><strong>ASTHMA AND SPECIFIC CONDITIONS AND POPULATIONS</strong></td>
<td>Asthma and pregnancy</td>
</tr>
<tr>
<td></td>
<td>Asthma in the elderly</td>
</tr>
<tr>
<td></td>
<td>Managing allergy &amp; asthma in resource poor settings</td>
</tr>
<tr>
<td></td>
<td>War-time asthma: Lessons from Syria</td>
</tr>
<tr>
<td></td>
<td>Asthma in children less than 5 years old</td>
</tr>
<tr>
<td></td>
<td>Asthma in teenagers</td>
</tr>
<tr>
<td><strong>ASTHMA CO-MORBIDITIES</strong></td>
<td>Asthma and rhinitis</td>
</tr>
<tr>
<td></td>
<td>Asthma and upper airways dysfunction</td>
</tr>
<tr>
<td></td>
<td>Obesity and asthma</td>
</tr>
<tr>
<td></td>
<td>Asthma and psychological problems</td>
</tr>
<tr>
<td></td>
<td>The asthma-COPD overlap</td>
</tr>
<tr>
<td></td>
<td>Atopic dermatitis</td>
</tr>
<tr>
<td></td>
<td>Chronic rhinosinusitis and Th2 inflammation</td>
</tr>
<tr>
<td><strong>ASTHMA DIAGNOSIS</strong></td>
<td>Under and overtreatment of asthma</td>
</tr>
<tr>
<td></td>
<td>Standards for the diagnosis of asthma</td>
</tr>
<tr>
<td></td>
<td>Pulmonary function tests</td>
</tr>
</tbody>
</table>
### ASTHMA EPIDEMIOLOGY

- Incidence and prevalence of asthma in the world
- Morbidity and mortality from asthma
- Lung function decline and its determinants
- Age and gender differences
- Natural history of asthma: Can it be altered
- Asthma remissions
- Does the “hygiene hypothesis” still hold?

### ASTHMA PATHOPHYSIOLOGY

- Airway inflammation
- Epithelial dysfunction
- Airway remodeling
- Neurogenic factors

### ASTHMA PHENOTYPES

- Asthma phenotyping: Practical aspects
- Asthma endotyping: Is it worth doing?
- Severe asthma
- Occupational asthma
- Asthma in the athlete
- Eosinophilic asthma
- Non-eosinophilic asthma
- Cluster analysis of asthma phenotypes
- Th17 immune responses in asthma
- Innate lymphocyte type 2 driven asthma
- Aspirin exacerbated respiratory disease
### ASTHMA TREATMENT

- Adherence to therapy: A major asthma management problem
- Inhaler techniques
- Initial treatment of asthma: When to introduce ICS?
- New inhalers
- Future treatment of asthma
- Non-pharmacologic asthma therapies
- Efficacy of bronchothermoplasty in asthma
- LAMA versus LABA for asthma
- Allergic moderate to severe asthma treatment options
- Impact of new asthma biologicals on asthma exacerbations and lung function

### ATOPIC DERMATITIS

- Pathophysiology- similarities and differences from asthma
- The allergic March
- New therapies- topical
- New therapies- biologics

### CLINICAL ASPECTS OF ASTHMA: THE PATIENT PERSPECTIVE

- Perception of asthma symptoms
- Patients’ expectations
- Patient opinions on asthma treatment
- The expert patient
### DRUGS FOR ASTHMA AND COPD

- β2-agonists
- Inhaled corticosteroids
- Anti-cholinergics
- Leukotriene antagonists
- Combination therapies (double and triple combinations)
- Monoclonal antibodies

### EDUCATIONAL INTERVENTIONS

- Asthma education and knowledge translation
- Educational interventions in COPD
  - Motivational interview
  - Shared-decision making
  - The asthma action plan
  - Role of the expert-patient
  - Training educators

### ENVIRONMENTAL FACTORS AND ASThma

- Allergens
- Workplace inhalants
- Air pollution
- Weather conditions (thunderstorms)
- Climate change

### FOOD ALLERGY

- New developments
- Management
- Role in asthma
- Peanut allergy therapeutic approaches
## GINA AND GOLD 2018 UPDATE
- New GINA report
- New GOLD report
- Asthma-COPD overlap report
- GINA-GOLD implementation program

## MAST CELL ACTIVATION SYNDROME
- Pathophysiology
- Associated conditions
- Diagnostic criteria
- Differential diagnosis
- Treatment options

## NON-INVASIVE AIRWAY INFLAMMATION ASSESSMENT
- Induced sputum analysis
- Exhaled NO measures

## PRECISION MEDICINE
- Personalized medicine: How to make it happen
- Biomarkers of asthma
- Targeting asthma therapy
- IL5 versus IgE as a therapeutics target in asthma
  - Anti-IgE
  - Anti-IL5
  - Other cytokines antagonists
# RESPIRATORY INFECTIONS AND ASTHMA

- Bacterial infections
- Viral infections
- Other agents
- Influence of vaccination

# RISK FACTORS OF ASTHMA

- Vitamin deficiency and nutritional factors
- Smoking (direct and secondary)
- Exposure to bacteria (microbiome)
- Genetic factors

# SEVERE ASTHMA

- Assessment of severe asthma
- Management of difficult-to-control asthma
  - Severe pediatric asthma
  - New monoclonal antibodies
  - Thermoplasty update
- Can we predict response to therapies
- New therapies to come
CALL FOR ABSTRACTS

Call for abstracts
The Scientific Committee welcomes the electronic submission of Abstracts to meet International Ethical Standards for Oral or e-Poster Presentations at the World Congress of Asthma 2018. All submitted abstracts will be evaluated by the Reviewers who deserve the right to propose a different type of presentation than the one selected by the Author. The abstracts will be published on CD-ROM and will be available for download on the WCA-2018 website. If the abstract is accepted, copyright will be held by Interasma.

For more information please contact abstracts@wca-2018.com

REGISTRATION

<table>
<thead>
<tr>
<th>Categories</th>
<th>Early Bird until June 30, 2018</th>
<th>Medium from July 01, 2018</th>
<th>Late/onsite from Sept 03, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members</td>
<td>550 €</td>
<td>680 €</td>
<td>750 €</td>
</tr>
<tr>
<td>Non Members</td>
<td>650 €</td>
<td>750 €</td>
<td>850 €</td>
</tr>
<tr>
<td>Allied Professionals*</td>
<td>400 €</td>
<td>440 €</td>
<td>490 €</td>
</tr>
<tr>
<td>Trainees**</td>
<td>350 €</td>
<td>380 €</td>
<td>420 €</td>
</tr>
<tr>
<td>Japanese Society Members</td>
<td>400 €</td>
<td>450 €</td>
<td>500 €</td>
</tr>
<tr>
<td>Japanese Non Members</td>
<td>450 €</td>
<td>500 €</td>
<td>550 €</td>
</tr>
<tr>
<td>Students</td>
<td>0 €</td>
<td>50 €</td>
<td>100 €</td>
</tr>
</tbody>
</table>

Registration for Specialists, Residents and Other Health Professionals includes:
- Access to the Congress scientific sessions
- Access to the Exhibition & Poster area
- Congress bag & documentation
- Lunches (as will be indicated)
- Coffee Breaks
- Welcome & Closing Reception access
Registration for Students includes:
- Access to the Congress scientific sessions
- Access to the Exhibition & Poster area
- Program at a glance
- Certificate of attendance

* Available for: Allied health professionals such as nurses, physiotherapists, technologists, non clinical scientists undertaking lung-related research, post-graduate, not medically qualified, and not directly involved in patient care.

** Registration fee applies for those under the age of 35. Trainees should provide a letter from their employer/institution.

Cancellation Policy
Cancellations of confirmed registrations are subject to a charge of 75€ per participant, provided the notice of cancellation is received no later than August 15, 2018. No refunds will be made for cancellations received after this date.

Name Change
Replacements (=delegate name change) of confirmed registrations after August 15, 2018 are subject to an administrative fee of 25€ per participant.
# Preliminary Programme

## October 3th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td><strong>Registration</strong></td>
</tr>
</tbody>
</table>
| 10:00 - 11:30 | **Asthma**<br><br>**Chairs:** Canonica G.W., Hashimoto S., Adachi M.  
**Asthma: General management**  
**J. Christian Virchow, Germany**  
**Eosinophilic & non-eosinophilic asthma**  
**Nelson Rosario, Brazil**  
**Patient's expectation on asthma treatment**  
**Fulvio Braido, Italy**  
**Asthma plan**<br><br>**Chairs:** Ansotegui I., Iwanaga Ta., Horiguchi T.  
**Asthma education and knowledge translation**  
**Louis Philippe Boulet, Canada**  
**Shared decision making**  
**Ho Joo Yoon, Korea**  
**The choice of anti-IL-5 in asthma**  
**Marina Labor, Croatia** |
| 11:30 - 12:30 | **Plenary lectures**<br><br>**Chairs:** DuBuske L., Ohta K., Ichinose M.  
**Asthma-COPD overlap: Implication for therapy** • **Peter Barnes, UK**  
**Allergic Rhinitis: Today and tomorrow** • **Jean Bousquet, France** |
| 12:30 - 12:45 | **Break**                                                               |
| 12:45 - 13:45 | **Luncheon Seminar**<br><br>(Company supported)                         |
| 13:45 - 14:00 | **Break**                                                               |
| 14:00 - 15:00 | **Asthma exacerbations**<br><br>**Chairs:** Boulet L.P., Nishimura Y., Sano Y.  
**Effect of air pollution on allergic rhinitis and asthma**  
**Ignacio Ansotegui, Spain**  
**Causes and risk factors**  
**Hiromasa Inoue, Japan**  
**Asthma treatable traits**<br><br>**Chairs:** Pawankar R., Kanehiro A., Sagara H.  
**Clinical control**  
**Fanny Wai-san Ko, China**  
**Molecular diagnosis of allergic sensitization in patients with respiratory diseases**  
**Mario Sanchez Borges, Venezuela** |
### October 3th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:00 - 16:30 | **Rhinitis and asthma**  
*Chairs:* Bousquet J., Kobayashi H., Ohta K.  
- The ARIA initiative  
  *Jean Bousquet,* France  
- Allergic rhinitis and asthma  
  *Shigeharu Fujieda,* Japan  
- Chronic rhinosinusitis/Nasal polyps and asthma  
  *G. Walter Canonica,* Italy |
|            | **WAO symposium**  
*Chairs:* Nagata M., Morikawa A.  
- WAO initiatives on severe asthma and immunotherapy  
  *Ignacio Ansotegui,* Spain  
- IgE in immunologic disorders and urticaria  
  *Mario Sanchez Borges,* Venezuela  
- Biomarkers and biologics in asthma and rhinitis  
  *Ruby Pawankar,* Japan |
| 16:30 - 17:00 | Break                                                                 |
| 17:00 - 18:30 | **Immunotherapy update**  
*Chairs:* DuBuske L., Yamaguchi M., Urisu A.  
- Immunological mechanism of AIT +/- clinical benefits and risk (both SLIT and SCIT)  
  *Moises Calderon,* UK  
- SLIT in management of HDM allergic rhinitis  
  *Kimihiro Okubo,* Japan  
- SLIT in management of HDM allergic asthma  
  *J. Christian Virchow,* Germany |
| 18:30 - 19:30 | **Opening ceremony**  
Followed by poster section (with light dinner)  
*Chairs:* Lawrence DuBuske, USA, Ken Ohta, Japan |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:30</td>
<td>Oral Communication</td>
</tr>
<tr>
<td>09:30 - 10:30</td>
<td><strong>Plenary lectures</strong>&lt;br&gt;<em>Chairs:</em> Boulet L.P., Niimi A., Nagase T.</td>
</tr>
<tr>
<td></td>
<td>Personalized &amp; precision medicine in asthma</td>
</tr>
<tr>
<td></td>
<td><strong>G. Walter Canonica, Italy</strong></td>
</tr>
<tr>
<td></td>
<td>Airway remodeling</td>
</tr>
<tr>
<td></td>
<td><strong>Peter Barnes, UK</strong></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td><strong>Environment and the lung</strong>&lt;br&gt;<em>Chairs:</em> Kowal K., Adachi Y., Hisada T.</td>
</tr>
<tr>
<td></td>
<td>Allergens</td>
</tr>
<tr>
<td></td>
<td><strong>Lawrence DuBuske, USA</strong></td>
</tr>
<tr>
<td></td>
<td>Occupational allergens</td>
</tr>
<tr>
<td></td>
<td><strong>Kunio Dobashi, Japan</strong></td>
</tr>
<tr>
<td></td>
<td>Impact of the lifestyle on asthma</td>
</tr>
<tr>
<td></td>
<td><strong>Lies Lahousse, Belgium</strong></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Break</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td><strong>Luncheon Seminar</strong>&lt;br&gt;(Company supported)</td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td>Break</td>
</tr>
</tbody>
</table>
### October 4th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs/Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 15:30</td>
<td><strong>Assessment of airways diseases</strong>&lt;br&gt;Chair: Canonica G.W., Nagase H., Dobashi K.</td>
<td>Basics for diagnosis&lt;br&gt;&lt;br&gt;&lt;em&gt;J. Christian Virchow&lt;/em&gt;, Germany&lt;br&gt;Allergy testing&lt;br&gt;&lt;em&gt;Krzysztof Kowal&lt;/em&gt;, Poland&lt;br&gt;Forced oscillation technique&lt;br&gt;&lt;em&gt;Hajime Kurosawa&lt;/em&gt;, Japan</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma drugs optimal usage</strong>&lt;br&gt;Chair: Santus P., Hirata K., Adachi M.</td>
<td>ICS/LABA&lt;br&gt;&lt;em&gt;Andras Bikov&lt;/em&gt;, Hungary&lt;br&gt;Anticholinergics&lt;br&gt;&lt;em&gt;Masakazu Ichinose&lt;/em&gt;, Japan&lt;br&gt;&lt;em&gt;Rohit Katial&lt;/em&gt;, UK</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td><strong>Pediatric asthma</strong>&lt;br&gt;Chair: Calderon M., Ohshima Y., Odajima H.</td>
<td>Treatment of mild to moderate asthma in children&lt;br&gt;&lt;em&gt;Nelson Rosario&lt;/em&gt;, Brazil&lt;br&gt;Approach to severe pediatric asthma&lt;br&gt;&lt;em&gt;Gary Wong&lt;/em&gt;, China&lt;br&gt;Management of exacerbation in children&lt;br&gt;&lt;em&gt;Yuichi Adachi&lt;/em&gt;, Japan</td>
</tr>
<tr>
<td></td>
<td><strong>Targeting asthma therapy</strong>&lt;br&gt;Chair: DuBuske L., Hoshino T., Kaneko T.</td>
<td>Anti-IgE&lt;br&gt;&lt;em&gt;Jean Bousquet&lt;/em&gt;, France&lt;br&gt;Eosinophilic inflammation&lt;br&gt;&lt;em&gt;Ronald Dahl&lt;/em&gt;, Denmark&lt;br&gt;Targeting non-T2 asthma&lt;br&gt;&lt;em&gt;Peter Barnes&lt;/em&gt;, UK</td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td><strong>Guidelines update</strong>&lt;br&gt;Chair: Ko F.W., Arakawa H., Ichinose M.</td>
<td>New classification of allergic diseases&lt;br&gt;&lt;em&gt;Jean Bousquet&lt;/em&gt;, France&lt;br&gt;Adult asthma 2018&lt;br&gt;&lt;em&gt;Louis Philippe Boulet&lt;/em&gt;, Canada&lt;br&gt;Pediatric asthma 2018&lt;br&gt;&lt;em&gt;Takao Fujisawa&lt;/em&gt;, Japan</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma in specific population</strong>&lt;br&gt;Chair: Braid F., Asai S., Tohda Y.</td>
<td>What is safe enough - asthma in pregnancy&lt;br&gt;&lt;em&gt;Marina Labor&lt;/em&gt;, Croatia&lt;br&gt;Asthma in the elderly&lt;br&gt;&lt;em&gt;Pierachille Santus&lt;/em&gt;, Italy&lt;br&gt;Lessons from real-life research in asthma&lt;br&gt;&lt;em&gt;David Price&lt;/em&gt;, Australia</td>
</tr>
<tr>
<td>17:30 - 19:00</td>
<td><strong>General assembly</strong></td>
<td></td>
</tr>
</tbody>
</table>
### October 5th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td><strong>Oral Communication</strong></td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td><strong>Plenary lectures</strong>&lt;br&gt;Chairs: Shimojo N., Yamaguchi M.</td>
<td>Asthma immunology&lt;br&gt;&lt;strong&gt;Lawrence DuBuske, USA&lt;/strong&gt;&lt;br&gt;New strategy for asthma treatment in the real world (including biologics)&lt;br&gt;&lt;strong&gt;David Price, UK&lt;/strong&gt;&lt;br&gt;New concepts of immunology - “Regulatory T cells”&lt;br&gt;&lt;strong&gt;Shimon Sakaguchi, Japan&lt;/strong&gt;</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td><strong>Diagnosis Section</strong>&lt;br&gt;Chairs: Braido F., Ishizuka T., Niimi A.</td>
<td>Noninvasive assessment of airway inflammation&lt;br&gt;&lt;strong&gt;G. Walter Canonica, Italy&lt;/strong&gt;&lt;br&gt;Pulmonary function test in obstructive airways diseases&lt;br&gt;&lt;strong&gt;Satoshi Konno, Japan&lt;/strong&gt;&lt;br&gt;What’s new in the elderly asthma?&lt;br&gt;&lt;strong&gt;Sang Heon Cho, Korea&lt;/strong&gt;</td>
</tr>
<tr>
<td>12:00 - 12:15</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td><strong>Luncheon Seminar</strong>&lt;br&gt;(Company supported)</td>
<td></td>
</tr>
<tr>
<td>13:15 - 13:30</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
</tbody>
</table>
## October 5th

### 13:30 - 15:00  
**Asthma & infections**  
*Chairs: Bikov A., Fujisawa T., Tokuyama K.*  
Asthma and virus  
**Shigemi Yoshihara, Japan**  
The importance of vaccinations for asthmatics  
**Gary Wong, China**  
Small interfering RNA treatments for viral asthma  
**Musa Khaitov, Russia**

### 15:00 - 17:00  
**Contributing factors for asthma**  
*Chairs: Boulet L.P., Tagaya E., Nagase T.*  
Genetic factors  
**Nobuyuki Hizawa, Japan**  
Microbiome and allergic airways disease  
**Ruby Pawankar, Japan**  
Asthma COPD overlap  
**Tsutomu Tamada, Japan**

### 17:00 - 17:30  
**Break**

### 17:30 - 19:00  
**New deal in asthma**  
*Chairs: Cho SH, Yamaguchi M., Iwanaga To*  
Precision medicine and biomarkers  
**Ronald Dahl, UK**  
Group 2 innate lymphoid cells and asthma  
**Kazuyo Moro, Japan**  
Influence of global warming on allergy and respiratory diseases  
**Nelson Rosario, Brazil**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:30</td>
<td>Oral Communication</td>
<td>Plenary lectures&lt;br&gt;Chairs: Bernstein J., Sagara H., Ohta K.&lt;br&gt;Severe refractory asthma&lt;br&gt;Joshua Boyce, USA&lt;br&gt;New concepts of immunology and cell biology - “Autophagy”&lt;br&gt;Noboru Mizushima, Japan&lt;br&gt;World incidence, prevalence and burden of asthma&lt;br&gt;Louis Philippe Boulet, Canada</td>
</tr>
<tr>
<td>09:30 - 11:00</td>
<td>Plenary lectures&lt;br&gt;Chairs: Bernstein J., Sagara H., Ohta K.</td>
<td>Severe refractory asthma&lt;br&gt;Joshua Boyce, USA&lt;br&gt;New concepts of immunology and cell biology - “Autophagy”&lt;br&gt;Noboru Mizushima, Japan&lt;br&gt;World incidence, prevalence and burden of asthma&lt;br&gt;Louis Philippe Boulet, Canada</td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>Asthma: Prevention and management&lt;br&gt;Chairs: Braido F., Nishimura Y., Takizawa H.</td>
<td>Biomarkers relevant for the clinician&lt;br&gt;Jonathan Bernstein, USA&lt;br&gt;Long-term management&lt;br&gt;Nelson Rosario, Brazil&lt;br&gt;Prevention of airway remodeling&lt;br&gt;Andras Bikov, Hungary&lt;br&gt;Asthma treatment&lt;br&gt;Chairs: Boulet L.P., Tsuburai T., Ishii Y.</td>
</tr>
<tr>
<td>12:30 - 12:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>12:45 - 13:45</td>
<td>Luncheon Seminar&lt;br&gt;(Company supported)</td>
<td></td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
# Preliminary Programme

## October 6th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 15:30</td>
<td><strong>Asthma clustering</strong>&lt;br&gt;&lt;i&gt;Chairs: DuBuske L., Nagase H., Taniguchi M.&lt;/i&gt;&lt;br&gt;Asthma phenotyping: Is it worth doing?&lt;br&gt;&lt;b&gt;Jonathan Bernstein&lt;/b&gt;, USA&lt;br&gt;Cluster analysis of asthma phenotypes&lt;br&gt;&lt;b&gt;Koichi Fukunaga&lt;/b&gt;, Japan&lt;br&gt;AERD&lt;br&gt;&lt;b&gt;Joshua Boyce&lt;/b&gt;, USA</td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td><strong>Closing Ceremony</strong></td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

Congress Venue
Keio Plaza Hotel 2-2-1 Nishi-Shinjuku, Shinjuku-Ku, Tokyo 160-8330 Japan

Climate
Fall (autumn) in Japan lasts from about mid-September to early December, depending on the location. Autumn is widely considered to be the most pleasant time (weather-wise) to visit Japan, with temperatures ranging from 12-18°C approximately.

Dress Code
The dress code will be Semiformal throughout the Congress.

Currency
The currency in Japan is yen, denoted by ¥. Coins come in denominations of ¥1, ¥5, ¥10, ¥50, ¥100, and ¥500.

Language
The official language of the Congress is English.

Local Time
The time zone in Tokyo is JST (Japan Standard Time) UTC/GMT +9 hours.

Visa
Any foreign visitor who wishes to enter Japan must have a passport, which will remain valid during the period of stay. In order to enter Japan, visitors usually must comply with the conditions of their visas and authorizations of resident eligibility. However, visa exemptions can be made for citizens of sixty-six different countries provided that their stays are within ninety days such as with stays for sightseeing purposes and that they do not engage in activities where they earn compensation. This page provides information on short stays. Revisions in visa conditions are made periodically. Therefore, please check the “Visa” section in the Ministry of Foreign Affairs of Japan website if the latest and detailed information on standard visas or visas other than for those for short stay programs is needed.

Travel and Health Insurance
It is strongly recommended that all participants purchase adequate coverage for health, travel and private liability insurance before departing from their home countries. The Organizers will not accept responsibility for personal injury, loss or damage to private, personal property of participants, accompanying persons and exhibitors.
About Tokyo
Tokyo, a metropolis like no other, offers you unique and inspiring moment by the marvelous mixture of traditional and contemporary attractions.

The most popular historical place is Asakusa’s Sensoji Temple and Nakamise Road, a colourful street of festive stalls, which are always bustling with local worshippers and tourists alike. Many UNESCO Intangible Cultural Heritage productions in the world-famous arts of Kabuki, Bunraku, and Noh are offered at various theatres. Visitors can also observe and practice the Zen-inspired tea ceremony, as well as Ikebana, an elegant traditional form of flower arrangement.

At the same time, Tokyo is a growing megalopolis bursting with ideas and innovation. Throughout the city are examples of ultra-modern and glass-walled skyscrapers, like the magnificent Tokyo Metropolitan Government building near Shinjuku Station. The sights and sounds of Western music and youth culture keep Shibuya constantly vibrant, and the bustle of modern business means things are never slow in the Shinagawa area. The Ginza and Yurakucho areas are the heart of big business and gorgeous architecture. The Omotesando Hills complex (designed by Tadao Ando), Tokyo Midtown, Shiodome skyscrapers, and the TOKYO SKYTREE are all symbolic of Japan’s ever-furthering venture for modernity.

Autumn in Tokyo is one of the most pleasant seasons, as temperatures are neither too cold nor too hot, and you often are treated to fine days with clear skies*. Chrysanthemums, the national flower, bloom to create beautiful displays of abundant flora that enchant visitors.

A.M.C./ Core P.C.O.

FREI S.A.
Congresses - Conventions - Exhibitions – Incentives
E-mail: info@interasma.org, info@wca-2018.com
Web: www.wca-2018.com

Local P.C.O.

Convention Academy Inc.
Tel.: +81 (0)3 5805 5261
Fax: +81 (0)3 3815 2/028
E-mail: anami@coac.co.jp